Please assess the completion status of the following clinical trial:

Trial Title: Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent by subject or guardian~2. 18 to 65 years of age (inclusive 18 and 65), male or female~3. Diagnosis of SLE according to the American College of Rheumatology criteria (1997)~4. Diagnosis of Class Ⅲ,Ⅳ,Ⅴ,Ⅲ+Ⅴand Ⅳ+ⅤLN according to the ISN/RPS 2003 classification by light, immunofluorescence, and electron microscopy within 6 months before enrollment~5. Pathologic chronic index (CI) ≤3' without thrombotic microangiopathy (TMA)~6. SLE Disease Activity Index (DAI) \>10'~7. Proteinuria ≥1.5g/d，with or without active urinary sediment~8. Serum creatinine (Scr)≤3.0mg/dl (265.2 mol/L)~Exclusion Criteria:~1. Previous treatment with MMF, CTX, tacrolimus, Cyclosporin A (CsA), large doses of immunoglobulin and methylprednisolone (MP), plasmapheresis or renal replacement therapy within the past 12 weeks. Oral glucocorticoids, azathioprine, intravenous MP (≤80mg/d)， short-time CsA (\<2 weeks) or leflunomide (\<4 weeks) are allowed~2. ALT or AST increase twice above the upper limit of the normal range~3. Hyperglycemia is defined as fasting blood glucose level ≥7.0 mmol/L and/or postprandial blood sugar level\>11.1 mmol/L~4. Known hypersensitivity or contraindication to any components of MMF, tacrolimus, CTX or glucocorticoids~5. History of present illness:~   1. active HBV infection (HBsAg, HBeAg and anti-HBc positive or HBsAg, anti- HBe and anti-HBc positive), HCV infection, pulmonary tuberculosis, cytomegalovirus(CMV) infection (defined as CMV-IgM positive or CMV-DNA positive), fungal infection or HIV infection, within 3 months before the enrollment~  2. non-healed active peptic ulcer within 3 months before the enrollment~  3. drug or drinking abuse~  4. malnutrition (BMI \<18.5kg/m2) or body weight \<50Kg~6. Other active diseases, such as:~   1. severe cardiovascular diseases~  2. chronic obstructive pulmonary disease(COPD)or asthma requiring oral glucocorticoids~  3. marrow depression not due to SLE activation: white blood cell count \<3000/mm3 or neutrophil count \<1300/mm3 or platelet count \<50000/mm3~7. Severe infection or need of antibiotic therapy~8. Female patients who are pregnant/breastfeeding or those patients (both gender) who refused contraception~9. Life-threatening complications such as large hydropericardium, pneumohemorrhagia, lupus encephalopathy and severe pulmonary hypertension or patients in need of MP pulse (\>0.5g/d ) treatment because of aggravation of SLE~10. Known to be non-compliance or violation of the protocol base on investigator's judgement~11. Patient who participate of any other investigational drug study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tacrolimus+Mycophenolate mofetil (Type: EXPERIMENTAL): FK506 4mg/d+MMF 1.0g/d
- Cyclophosphamide (Type: ACTIVE_COMPARATOR): CTX iv 0.75 g/m2 body surface area (BSA)

Based on this trial design, predict the completion outcome and termination type (if applicable).